Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue Journal of Thrombosis and Haemostasis Année : 2016

Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor

Résumé

In clinical studies, thromboprophylaxis with low-molecular-weight heparins (LMWHs) has been demonstrated to reduce the risk of venous thromboembolism and to improve outcomes in cancer patients. Moreover, preclinical models have previously suggested that LMWHs may also offer additional benefits through direct antitumor properties. However, the optimal doses of LMWHs that may prevent both cancer-related thrombosis and tumor development are yet unknown.
Fichier non déposé

Dates et versions

hal-01451070 , version 1 (31-01-2017)

Identifiants

Citer

Corinne Frere, Soraya Mezouar, Léa Plantureux, Lydie Crescence, Laurence Panicot-Dubois, et al.. Optimal doses of tinzaparin to reduce both cancer-associated thrombosis and tumor growth in a mouse model of ectopic pancreatic syngeneic tumor. Journal of Thrombosis and Haemostasis, 2016, 14, pp.76-76. ⟨10.1016/S0049-3848(16)30167-0⟩. ⟨hal-01451070⟩

Collections

UNIV-AMU
22 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More